- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | AEON Biopharma Inc: AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer | 382 | GlobeNewswire (Europe) | - Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory... ► Artikel lesen | |
| 19.08. | AEON Biopharma Inc: AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX | 414 | GlobeNewswire (Europe) | - Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed... ► Artikel lesen | |
| 17.08. | H.C. Wainwright senkt Kursziel für Aeon Biopharma Aktie wegen Verwässerung | 1 | Investing.com Deutsch | ||
| AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 17.08. | H.C. Wainwright cuts Aeon Biopharma stock price target on dilution | 2 | Investing.com | ||
| 13.08. | AEON Biopharma Q2 Non-GAAP EPS of -$0.02 | 1 | Seeking Alpha | ||
| 12.08. | AEON Biopharma Inc: AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 174 | GlobeNewswire (Europe) | - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program... ► Artikel lesen | |
| 12.08. | AEON Biopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.08. | AEON Biopharma regains NYSE American listing compliance after $13.6M offering | 1 | Seeking Alpha | ||
| 03.08. | AEON Biopharma Inc: AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards | 116 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX... ► Artikel lesen | |
| 23.07. | AEON Biopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | AEON Biopharma prices $13.75M offering with milestone warrants | 1 | Seeking Alpha | ||
| 14.07. | AEON Biopharma Inc: AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding | 194 | GlobeNewswire (Europe) | IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA)... ► Artikel lesen | |
| 09.07. | AEON Biopharma, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 08.07. | AEON Biopharma, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 17.06. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | AEON Biopharma Inc: AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society | 2 | GlobeNewswire (USA) | ||
| 15.05. | AEON Biopharma-Aktie fällt nach Quartalsverlust um über 2 % | 1 | Investing.com Deutsch | ||
| 15.05. | AEON Biopharma GAAP EPS of -$0.29 | 1 | Seeking Alpha |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| ABIVAX | 97,45 | -0,31 % | Abivax-Aktie: Zulassungsantrag rückt näher - Übernahme auch? | Die Abivax-Aktie steht vor einer entscheidenden Phase: Nach starken Phase-3-Daten, konstruktivem FDA-Feedback und einer prall gefüllten Kasse rückt der geplante Zulassungsantrag für Obefazimod in den... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,320 | 0,00 % | ALTERITY THERAPEUTICS LTD - 20-F, Annual and transition report of foreign private issuers | ||
| APTEVO THERAPEUTICS | 2,365 | +0,64 % | Aptevo Therapeutics: Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results | Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology PipelineNon-Dilutive Grant... ► Artikel lesen | |
| BIOCURE TECHNOLOGY | 0,023 | 0,00 % | CSE Bulletin: Halted for Fundamental Change - Biocure Technology Inc. (CURE.X) | Le 13 août/August 2026
Trading in the shares of Biocure Technology Inc. (CURE.X) will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Change pursuant... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | DAX Verlierer: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Moderna Aktie: Was für ein Wahnsinn bei Moderna! Kippt aber jetzt die Stimmung?! | © Foto: Finanznachrichten (Symbolbild wurde mit KI erstellt)Erst ein Kurssprung wie ihn kaum eine Aktie je erlebt hat, dann der schnelle Absturz, aber kommt jetzt wieder eine Erholung? Moderna sorgt... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen |
Das Unternehmen AEON BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,311 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AEON BIOPHARMA INC finden Sie auf Wallstreet Online.